J&J, Boston Scientific release drug-coated stent safety reports

10/21/2007 | Bloomberg

Patients who received Johnson & Johnson's drug-coated stent Cypher have lower rates of blood clot recurrence compared with those who received bare-metal devices, while Boston Scientific Corp.'s Taxus stent was found to be as safe after two years for use in sicker heart patients as for use in those who were healthier, according to studies presented at a conference in Washington, D.C. "[Drug-eluting] stent safety is a hot-button topic, and the big question we see coming out of the meeting will be whether utilization picks back up," a market analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA